A Phase II Single-Blind Placebo-Controlled Sequential Treatment Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Donepezil with Solifenacin in Patients with Alzheimer's Disease Type Dementia

M
Martin Farlow, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.

Description

The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease Type Dementia
  • Age: Between 50 Years - 79 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1405058990

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center